You just read:

Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma

News provided by

Medicenna Therapeutics Corp.

Jun 18, 2019, 08:30 ET